Clinical Trial Update: Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery [NA]

View source ↗

Summary

Completed trial evaluating whether preoperative recombinant human erythropoietin reduces transfusion risk in valvular heart surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Valvular Heart Disease

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Yonsei University | Conditions: Cardiac Surgery | NA | Status: COMPLETED